No approval claim should jump from a named medicine to a different analogue merely because both names contain IGF-1. Product identity and the specific indication remain essential.
The INCRELEX label concerns mecasermin and defines particular pediatric growth-failure uses. It is not a label for Long R3 IGF-I. Its existence therefore cannot establish authorization, dosing or suitability for an LR3 research preparation.
Separate the citation from the commercial claim
A catalog page may link to an IGF paper or a medicine label for background. That link should not imply that the listed product is the same finished medicine, meets the same manufacturing requirements or has the same clinical evidence.
The quantity discrepancy in the current Serum Research LR3 title also remains a documentation problem, not something that can be repaired by borrowing a prescription label. A name and a number must be verified for the actual item.
A legitimate scientific summary can discuss related molecules while explicitly identifying which one was studied. The problem arises when an article drops that distinction and lets the reader infer equivalence.
For medical care, the relevant question is which authorized product the clinician is considering for which diagnosis in the applicable jurisdiction. For laboratory work, the question is whether the supplied material matches the intended research identity and analytical requirements. Neither is answered by a general family name.
This article is not a complete worldwide regulatory inventory or legal advice. It makes a narrower, defensible point: mecasermin's label cannot be transferred to LR3.
The same boundary applies to safety information. A warning in one product label may prompt a cautious research question, but it does not define the exact risk profile of a different analogue. Good evidence communication keeps both benefit and harm claims attached to the preparation actually evaluated.